This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cobiprostone Preclinical Data From NSAID-Induced Gastric Mucosal Injury Models Reported At Digestive Disease Week 2012

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of preclinical data at Digestive Disease Week 2012, in San Diego, which demonstrates the protective effect of cobiprostone (also known as SPI-8811) against epithelial barrier dysfunction in models of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury.

The poster entitled, “The Protective Effect of ClC-2 Agonist SPI-8811 on Indomethacin-induced Epithelial Barrier Dysfunction in Human Gastric Epithelial Cells,” was authored by Meghali Nighot and Anthony Blikslager, of NC State University College of Veterinary Medicine, and Ryuji Ueno, of Sucampo.

In the study presented, treatment with the NSAID indomethacin resulted in increased permeability due to dysregulation of occludin co-localization. The results of this in vitro study show that cobiprostone, via ClC-2 activation, can counter act such adverse effects of NSAID on tight junction proteins. Additionally, cobiprostone was shown to prevent indomethacin-induced cell death.

“NSAIDs are commonly prescribed drugs for pain, fever and inflammation, but are not ideal for long-term use because of the risk of ulcer formation,” said Anthony Blikslager, DVM, Ph.D., DACVS, NC State University, College of Veterinary Medicine. “In this study, we demonstrated that cobiprostone exerts a protective effect against epithelial barrier dysfunction in the presence of an NSAID in human gastric epithelial cells. Based on these data, we believe that cobiprostone could serve as a treatment option in patients taking NSAIDs.”

About cobiprostone

Cobiprostone is an investigational prostone compound under development by Sucampo Pharmaceuticals Inc. as a potential treatment for gastrointestinal, liver and respiratory diseases. Sucampo holds worldwide, exclusive rights to cobiprostone.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.

Sucampo Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo’s ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs